Joseph Monahan - Dec 31, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Dec 31, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 06:25 PM
Previous filing
Dec 12, 2024
Next filing
Feb 4, 2025

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -73.8K -50% $0.00 73.8K Dec 31, 2024 Common Stock 73.8K Direct F1, F3
transaction ACRS Restricted Stock Units Award $0 +52.7K $0.00 52.7K Jan 2, 2025 Common Stock 52.7K Direct F1, F4
transaction ACRS Restricted Stock Units Options Exercise $0 -17.4K -33% $0.00 35.3K Jan 2, 2025 Common Stock 17.4K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4 The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.